Jeremy S Abramson and colleagues reported that glofitamab plus gemcitabine and oxaliplatin (GemOx) significantly improved overall survival (OS) in transplant-ineligible patients with relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback